ReviewThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2021
Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review.
Review in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Unveiling the Link Between COVID-19 and Pulmonary Hypertension.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- The Role of Telehealth in PAH Management: Benefits, Barriers, and Solutions.Pulmonary circulation · 2025Article
- Depression in Pulmonary Hypertension: A Systematic Review of Clinical Outcomes, Treatment Interactions, and Emerging Technologies.Journal of clinical medicine · 2025Review
- Management of pulmonary hypertension in special conditions.The European respiratory journal · 2024Review
- Potential therapeutic targets for COVID-19 complicated with pulmonary hypertension: a bioinformatics and early validation study.Scientific reports · 2024Article
- Pulmonary vascular disease, environmental pollution, and climate change.Pulmonary circulation · 2024Review
- Remote exercise testing in pulmonary hypertension (PHRET).Pulmonary circulation · 2023Article
- Impact of the COVID-19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension-specific therapy in the United States of America: An observational study.Pulmonary circulation · 2023Article
- Human Endogenous Retrovirus, SARS-CoV-2, and HIV Promote PAH via Inflammation and Growth Stimulation.International journal of molecular sciences · 2023Review
- Pulmonary Hypertension and Measurement of Exercise Capacity Remotely: Evaluation of the 1-min Sit-to-Stand Test (PERSPIRE) - a cohort study.ERJ open research · 2023Article
- Management of COVID-19 in Patients with Pulmonary Arterial Hypertension.Heart failure clinics · 2023Review
- Effects of COVID-19 pandemic on the management of pulmonary hypertension.Respiratory medicine · 2023Article
- Pulmonary Hypertension Association's 2022 International Conference Scientific Sessions Overview.Pulmonary circulation · 2023Article
- The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?The European respiratory journal · 2022Article
- Comprehensive Review of Pulmonary Hypertension and Treatment Options in the Paediatric Population.Cureus · 2022Review
- Telehealth: A winning weapon to face the COVID-19 outbreak for patients with pulmonary arterial hypertension.Vascular pharmacology · 2022Article
- Pulmonary Vascular Research Institute GoDeep: A meta-registry merging deep phenotyping datafrom international PH reference centers.Pulmonary circulation · 2022Article
- Factors determining change in treatment for ambulatory children with pulmonary arterial hypertension: Implications for monitoring.Pulmonary circulation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients affected by pulmonary arterial hypertension (PAH) benefit from intensive, continuous clinical monitoring to guide escalation of treatments that carry the potential to improve survival and quality of life. During the coronavirus disease 2019 pandemic, the need for physical distancing has fueled the expeditious expansion of various telehealth modalities, which may apply in a unique manner to individuals with PAH. Performance of objective risk assessments in patients with PAH remotely via telemedical visits and other telehealth mechanisms is unprecedented and not yet rigorously validated. The uniquely high risk for rapid deterioration in patients with PAH demands a high degree of sensitivity to detect changes in functional assessments. In this review, several telehealth modalities for potential utilization in risk assessment and treatment titration in patients with PAH are explored, yet additional study is needed for their validation with the pre-pandemic care paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.